




RealRate

PHARMACEUTICAL 2019

PhaseBio Pharmaceuticals Inc
Rank 153 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of PhaseBio Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PhaseBio Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 286% points. The greatest weakness of PhaseBio Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -109%, being 223% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	62,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,577
Liabilities, Non-Current	7,500
Other Assets	43
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	22
Other Net Income	-4,202
Property and Equipment	355
Research and Development	15,455
Revenues	668
Selling, General and Administrative Expense	4,857

Output Variable	Value in 1000 USD
Assets	63,026
Liabilities	12,099
Expenses	20,312
Stockholders Equity	50,927
Net Income	-23,846
Comprehensive Net Income	-23,846
Economic Capital Ratio	-109%